Merck’s pause on an HIV program snowballs as a Gilead-partnered trial is shoved into limbo

Merck’s announcement last week that an experimental HIV combo therapy resulted in a drop in immune cell counts, and its subsequent decision to halt a Phase II study, is starting to see a snowball effect. Late Tuesday afternoon, the pharma giant and partner Gilead said they are pausing enrollment of…

...

Click to view original post